Cystic fibrosis examine measures are the most recent augmentations to Canon BioMedicals Novalleleu genotyping library PR Newswire official statement

“”We are excited to launch these new CFTR assays and add them to our Novallele genotyping assay library,” states Akiko Tanaka, CEO of Canon BioMedical. “Cystic fibrosis directly affects the quality of life of thousands of people, and we can only hope that our technologies will contribute to understanding this complex disease and assist with the ongoing therapeutic research.”
Complete details about the entire Novallele genotyping assays are available at www.canon-biomedical.com. In addition, Canon BioMedical will present the Novallele genotyping library at the American College of Medical Genetics and Genomics 2017 A
ual Meeting in Phoenix, Arizona, on March 21, 2017. Find us at Booth 412 in the exhibit hall to discover more about our new assays focused on cystic fibrosis research.
About Canon BioMedical
Canon BioMedical, a wholly owned subsidiary of Canon U.S.A., Inc., is focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing i
ovative technologies and solutions. The technologies and solutions developed will help enable clinicians and scientists to improve our health and advance science. Canon BioMedical will continue to pursue i
ovative solutions in line with Canon’s Kyosei philosophy of social and environmental responsibility through the use of existing and emerging Canon technology as well as strategic partnerships.”

Original link